- Home
- LCTX vs DTI Comparison
LCTX vs DTI Comparison
Compare LCTX & DTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- DTI
- Stock Information
- Founded
- LCTX 1990
- DTI 1984
- Country
- LCTX United States
- DTI United States
- Employees
- LCTX N/A
- DTI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- DTI Metal Fabrications
- Sector
- LCTX Health Care
- DTI Industrials
- Exchange
- LCTX Nasdaq
- DTI Nasdaq
- Market Cap
- LCTX 127.7M
- DTI 118.5M
- IPO Year
- LCTX N/A
- DTI N/A
- Fundamental
- Price
- LCTX $0.68
- DTI $3.02
- Analyst Decision
- LCTX Strong Buy
- DTI Strong Buy
- Analyst Count
- LCTX 4
- DTI 1
- Target Price
- LCTX $4.50
- DTI $5.50
- AVG Volume (30 Days)
- LCTX 1.2M
- DTI 43.1K
- Earning Date
- LCTX 03-06-2025
- DTI 03-26-2025
- Dividend Yield
- LCTX N/A
- DTI N/A
- EPS Growth
- LCTX N/A
- DTI N/A
- EPS
- LCTX N/A
- DTI 0.26
- Revenue
- LCTX $8,719,000.00
- DTI $149,789,000.00
- Revenue This Year
- LCTX N/A
- DTI $0.09
- Revenue Next Year
- LCTX $41.15
- DTI $10.53
- P/E Ratio
- LCTX N/A
- DTI $11.40
- Revenue Growth
- LCTX N/A
- DTI N/A
- 52 Week Low
- LCTX $0.48
- DTI $2.50
- 52 Week High
- LCTX $1.61
- DTI $6.36
- Technical
- Relative Strength Index (RSI)
- LCTX 53.39
- DTI 42.17
- Support Level
- LCTX $0.58
- DTI $3.05
- Resistance Level
- LCTX $0.73
- DTI $3.26
- Average True Range (ATR)
- LCTX 0.05
- DTI 0.14
- MACD
- LCTX 0.00
- DTI 0.00
- Stochastic Oscillator
- LCTX 50.67
- DTI 40.10
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About DTI Drilling Tools International Corporation
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The Company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The Company's international operations are located in Canada with additional stocking points in Europe and the Middle East.